iCo Therapeutics (iCo Therapeutics) Days Payable : 0.00 (As of Mar. 2021)

View and export this data going back to 2009. Start your Free Trial

What is iCo Therapeutics Days Payable?

iCo Therapeutics's average Accounts Payable for the three months ended in Mar. 2021 was $0.97 Mil. iCo Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2021 was $0.00 Mil.

The historical rank and industry rank for iCo Therapeutics's Days Payable or its related term are showing as below:

ICOTF's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 147.46
* Ranked among companies with meaningful Days Payable only.

iCo Therapeutics's Days Payable stayed the same from Mar. 2020 (0.00) to Mar. 2021 (0.00). stayed the same

iCo Therapeutics Days Payable Historical Data

The historical data trend for iCo Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iCo Therapeutics Days Payable Chart

iCo Therapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Days Payable

Get a 7-Day Free Trial

iCo Therapeutics Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of iCo Therapeutics's Days Payable

For the Biotechnology subindustry, iCo Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

iCo Therapeutics's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, iCo Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where iCo Therapeutics's Days Payable falls into.

iCo Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

iCo Therapeutics's Days Payable for the fiscal year that ended in Dec. 2020 is calculated as

	Days Payable (A: Dec. 2020 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2019 )	+	Accounts Payable (A: Dec. 2020 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2020 )	*	Days in Period
=	( (0.5	+	0.839)	/	2 )	/	0	*	365
=	0.6695					/	0	*	365
=	N/A

iCo Therapeutics's Days Payable for the quarter that ended in Mar. 2021 is calculated as:

	Days Payable (Q: Mar. 2021 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2020 )	+	Accounts Payable (Q: Mar. 2021 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2021 )	*	Days in Period
=	( (0.839	+	1.11)	/	2 )	/	0	*	365 / 4
=	0.9745					/	0	*	365 / 4
=	N/A

iCo Therapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of iCo Therapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

iCo Therapeutics (iCo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » iCo Therapeutics Inc (GREY:ICOTF) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

777 Hornby Street, 6th Floor, Vancouver, BC, CAN, V6Z 1S4

Website

http://www.icotherapeutics.com

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between the cells of the immune system. Geographically, it operates in Canada and Australia.

iCo Therapeutics (iCo Therapeutics) Headlines

No Headlines